In Europe, despite recent therapeutic advances, there are many deficiencies in the management of multiple sclerosis (MS). Diagnostic and monitoring measures, guidelines, development of new treatments and best practice care are often suboptimal. These shortcomings were discussed at two MS multi-stakeholder colloquia that were convened in Brussels, Belgium in May 2014 and May 2015, and gathered experts from a range of different specialities to identify the key issues and propose means of tackling them. After considering all the testimony and discussion, the organising committee drew up a list of 10 calls to action, which included: increase awareness and understanding in the EU about the burden of MS; obtain better insights into the direct and indirect cost burden of MS; (re)define treatment goals and clinical study endpoints; develop new tools to better capture the total clinical burden of MS; develop a protocol to standardise magnetic resonance imaging (MRI); develop biomarkers of treatment response prediction and disability progression; integrate drug licensing and cost-effectiveness decision-making processes; develop separate European Medicines Agency guidelines for evaluating follow-on products of non-biological complex drugs and biologicals; implement a set of evidence-based standards of care and incentives to support people with MS to remain physically and mentally active. Addressing these ambitious calls to action requires cooperation from various health bodies and governments and some will require additional funding, but they are achievable and worthwhile. They would help minimise disease impact and would reduce disease progression and the consequent burden on people with MS, their caregivers, and on health budgets. These calls to action set out a strategy for future MS management and should be acted upon with urgency.
Over the past two decades, advances in the availability of new treatments and understanding of the disease have significantly improved the prognosis for many people with multiple sclerosis (PwMS).
Despite this, in Europe, various aspects of management, diagnosis and monitoring of MS, the availability of guidelines, the development of new treatments and the provision of best-practice care are frequently suboptimal. Full awareness of the disease and its total burden is often lacking and patients' access to the most appropriate treatments is highly variable between different territories. Reasons for low adoption of innovations are complex and affected by cultural factors. In addition, the methods used to assess the disease and its progression have notable colloquia bring together healthcare professionals (HCPs), regulators, pharmacists, payers, economists and patient representatives. These gatherings of diverse disciplines enable valuable exchanges of views between sectors that infrequently interact. The colloquia were designed to initially identify and discuss the issues facing MS understanding and management in Europe and then to propose actions to address the issues identified. Based on this evidence, the scientific committee of the MS multi-stakeholder colloquia identified 10 key calls to action.
Addressing all these calls will require cooperation and funding from governments, healthcare organisations and payers, and active support from HCPs and patient groups. Such worthwhile actions may ultimately eliminate disparities in MS care levels in different countries in Europe, they could reduce the burden on patients and caregivers burden and improve long-term outcomes.
Increase awareness and understanding in the European community of the burden of multiple sclerosis on patients and caregivers
In the general population, among legislators and some healthcare providers, the extent of MS and its impact on younger populations is not widely recognised or understood. This decreases understanding of the scale of the problem and can restrict resources allocated to managing the disease. Worldwide, there are 2-2.5 million people living with MS, which is equivalent to 30 cases/100,000, including 600,000
in Europe with 1,000,000 associated caregivers and family members. 1 The prevalence of MS is higher in developed countries and at higher latitudes. Current data show that per 100,000 population, the rates are: 140 in Europe, 108 in North America, 2.1 in sub-Saharan Africa and 2.2 in Asia. [2] [3] [4] The mean age of onset of MS is 30 years 5 -a time of maximum work productivity -resulting in years of lost earnings in addition to extensive medical and care costs. PwMS can live with the disease for many decades, necessitating long-term care and increasing dependence on others (Figure 1 ).
In PwMS, moderate disability (Expanded Disability Status Scale [EDSS] score of 3),which is often reached in a few years, reduces health-related quality of life (HRQoL) to 0.56 (EQ5D-5L). This is a poorer quality of life (QoL) status than patients' experience with chronic ischaemic heart disease or noninsulin dependent diabetes mellitus. 6, 7 To help address some of these issues, various activities and initiatives of the European Multiple Sclerosis Platform (EMSP) are ongoing. These seek to improve public awareness of MS and increase understanding of the impact of MS for researchers and HCPs (Table 1) .
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Obtain better insights into the direct and indirect (patient and caregiver) cost burden of multiple sclerosis
The economic impact of MS is high but the exact costs (both direct and indirect) are insufficiently studied; recent figures may be underestimates of the true impact of the disease. MS generally strikes in mid-life; data from studies conducted during the last decade indicate that it has a very high cost burden compared with other brain conditions such as stroke, dementia, Parkinson's disease and epilepsy ( Figure 2) 13 despite having a lower prevalence than some other brain disorders (e.g. anxiety, migraine, addiction etc. 
DMT = disease-modifying treatment; EMSP = European Multiple Sclerosis platform; MS = multiple sclerosis; PwMS = people with multiple sclerosis
Power Parity). 16 Meanwhile, the total direct and indirect costs of MS in Europe have been estimated to be €31,000/patient/year ( Figure 3 
Perform patient research to (re)define treatment goals and clinical study endpoints from a humanistic/patient perspective
Patient and physician perspectives in MS frequently do not coincide. For disease effects that decrease QoL, physicians tend to prioritise physical aspects, whereas patients prioritise mental and emotional aspects, general health, relapses, disease progression and adverse events. 17, 18 This difference in attitude was emphasised by a web survey of 651 MS patients that revealed that treatment safety concerns (progressive multifocal leukoencephalopathy [PML] , liver failure and leukaemia)
were more important to them than reducing relapse rate. Reproduced with permission from Kobelt G, et al. 6 20 These factors should be as important as relapse rate and disability progression in drug approval/licensing and in value-formoney decision making by health authorities. QoL determination is a critical criterion in patient-reported MS treatment efficacy, but it is important to recognise that condition-specific measures do not capture comorbidities. To address this, a broad definition of QoL in MS as well as a generic EuroQol 5D test (EQ-5D) are needed.
Develop new tools to better capture the total clinical burden of multiple sclerosis
The measures used to determine the clinical burden of MS are not standardised, not uniformly applied and many provide incomplete or unsatisfactory assessments. The EDSS has been used for many years to assess disability progression, but it has limitations including poor inter-and intra-rater reliability and low sensitivity to small changes in disability. EDSS is less useful for patients with severe disability at baseline and captures only physical ability/mobility/motor skills. 21 Various other assessment scales are available in MS, including the Multiple Sclerosis Functional Composite (MSFC), 22 the Multiple Sclerosis Impairment Scale (MSIS), 23 the Family Assessment of Multiple Sclerosis Trial Outcome Index (FAMS-TOI) 24 and various others 25 but these also have limitations.
Some neurologists argue that scales that better capture the less visible symptoms such as cognition, fatigue and bladder, bowel and sexual function should be routinely used in MS. 26 For example, the Brief International Cognitive Assessment for MS 27 For example, future relapse risk increases with the initial number of T2 and contrast-enhanced lesions, 28, 29 and number and topography of lesions predicts long-term disability. 30, 31 Clinical observation of MS signs often fails to capture the extent of disease activity. Indeed, sub-clinical disease activity as detected by MRI, can be substantially greater than that indicated by clinical assessment of relapse. 32 In addition, MRI can capture some aspects of the neurodegenerative component of the disease, such as T1 hipointense lesions (a marker of focal irreversible tissue damage) and brain volume loss (a marker of brain atrophy). Significant associations have been reported between baseline T1 lesion count, 10-year T1 hypointense lesion volume and EDSS progression, 33 and measures of overall brain atrophy predict disability and disability progression. [34] [35] [36] Whilst MRI assesses many valuable markers of MS status, pathophysiology and likely progression, the protocols used vary substantially between different treatment centres and territories. In addition, access to MRI equipment, particularly the latest instruments, is inconsistent across Europe. Consequently, many patients receive delayed or incorrect diagnosis, insufficient disease monitoring and suboptimal treatment.
The lack of consistent protocols is emphasised by the variability in the methods used for measuring whole brain atrophy, the most robust MRI method to quantify the extent of brain tissue loss or damage, and in the varied capabilities of different centres to provide this measure.
There is, therefore, a pressing need for robust and standardised acquisition/interpretation MRI methodology in MS that could include decision tree algorithms. Furthermore, there is a need for accreditation of centres and radiologists to help ensure best MRI practice is provided across all European territories.
Support research to find other biomarkers to predict and monitor individual treatment response with regard to long-term disability progression
Other than MRI, there are few proven biomarkers for use in MS diagnosis, monitoring or treatment response. 37 There is a substantial unmet medical need for reliable biomarkers in MS that could be used in clinics and physicians' offices. Such biomarkers would be a valuable addition to clinical examination/symptoms and could increase confidence and speed in MS diagnosis and hasten the initiation of appropriate treatments. Immunoglobulin G OCB In CSF -predicts earlier conversion to CDMS 41, 42 IgG index In CSF -predicts disability progression 43 Immunoglobulin M OCB In CSF -predicts earlier conversion to CDMS and disease severity [44] [45] [46] [47] [48] HLA-DRB1*1501
polymorphism In blood 49 -associated with early disease onset, early progression from RRMS to SPMS and worse brain atrophy
Chitinase-3-like-1 In CSF -predicts earlier conversion to CDMS and disability progression 76, 77 Low vitamin D levels In blood -predicts earlier conversion to CDMS and disability progression 42, 50 Biomarkers Important in Treatment Selection 
CDMS = clinical definite multiple sclerosis; CSF = cerebrospinal fluid; INFβ = interferon beta; MS = multiple sclerosis; OCB = oligoclonal bands; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis
Several biomarkers show promise in MS diagnosis/monitoring ( Table 2) , these include several in CSF: neurofilament heavy and light chains, [38] [39] [40] [41] immunoglobulin G (IgG) oligoclonal bands (OCBs), 42, 43 IgG index, 44 and immunoglobulin M OCBs. [45] [46] [47] [48] [49] Biomarkers in blood include an HLA-DRB1*1501 polymorphism 50 and low vitamin D levels. 43, 51 Other biomarkers that inform treatment selection in MS include: neutralising antibodies (stimulated in response to interferon beta [IFNβ]), 52 anti-John Cunningham virus (JCV) antibodies, 53 L-selectin (CD62L) CD4+ T cells (natalizumab) 54 and possibly serum interleukin-21 (in response to alemtuzumab). 55, 56 Further research is needed in the quest for new and better MS biomarkers and in the validation of existing candidate biomarkers. Quality and Efficiency in Health Care (IQWiG) or payers such as insurance companies and pharmacies, and they emphasise value for money/cost effectiveness/affordability. 57 The HTAs have different remits and priorities for reimbursement 57, 58 and the lack of coordination between CHMP and HTAs results in widespread inequalities in access to MS treatment in different European territories (as shown by the MS Barometer and other studies, 8, 59 ( Figure 4 ). For example, fampridine received only conditional approval for improving mobility in MS because the CHMP was not convinced by patient-reported outcome data and demanded more studies. CHMP and HTAs have different objectives, so merging the two assessments would be difficult but adaptation or alignment of the functions may be possible. The function of HTAs is unclear/unknown to most patients; these bodies mostly comprise HCPs and payers. More patient involvement is needed in these authorities/committees to better reflect their perspectives and priorities.
Develop separate European Medicines Agency guidelines for evaluating follow-on products of non-biological complex drugs
As the patents of several older disease-modifying therapies (DMTs) are expiring, this opens the door to generic biosimilars and follow-on products. These have the potential to reduce the costs of MS treatment.
Biologicals such as interferons or monoclonals can be produced as biosimilars; these are similar to the original and can be characterised. have found that that 50% of patients with EDSS 3 and 80% of patients with EDSS 6 are unemployed or on long-term sick leave. 6, 70 To minimise disease impact, it is vital to establish and maintain centres of excellence, with a multidisciplinary care team to provide an integrated care pathway that contains evidence-based standards of care and well-defined healthcare objectives. These will help address all aspects of the disease and the challenges patients face.
Good patient management should involve patient activation (involvement in healthcare) and rehabilitation strategies to maintain health and QoL. 71, 72 These measures can help PwMS stay in work and reduce the disease and economic burden. Such services, however, are not available to all and C z e c h R e p u b li c D e n m a r k F in la n d G e r m a n y G r e e c e Ic e la n d Ir e la n d It a ly N o r w a y P o la n d P o r t u g a l R o m a n ia R u s s ia S e r b ia S lo v a k ia S p a in S w e d e n S w it z e r la n d U K 
Support continuation of multi-stakeholder colloquia
Interaction between stakeholders, including diverse professionals, patients and caregivers involved in MS management and its provision is valuable but rare. Most meetings in MS are confined to specific skill sets, notably neurologists, and involve few other specialities involved in the delivery of therapy to PwMS, nor do they include patients and their caregivers. Multi-stakeholder colloquia enable all involved in MS to gain insights and pass knowledge and experiences beyond the confines of their usual speciality or location. These meetings are uniquely placed to determine current opinions in MS management and aim to stimulate action to put pressure on governments and healthcare authorities to amend practices and policies that currently hinder best practice.
The multi-stakeholder colloquia should therefore continue as long as PwMS across Europe do not have equal access to optimal treatments or receive adequate support measures to help manage their disease.
Conclusions
The calls to action discussed above are ambitious; addressing them will require active involvement and support from key stakeholders including governments and healthcare organisations. Some calls will require allocation of significant additional funding for provision of treatments or research programmes. Some of the calls urge prompt adoption of best practice but agreement on standard protocols will require cooperation of medical organisations across regions. This may be challenging but appears achievable. Improving awareness of MS and its burden also seems achievable given cooperation between different stakeholders.
Addressing the calls will likely improve the situation of many PwMS and help retard disease progression, reduce their burden on caregivers and maintain them in employment for longer. This could provide greater economic benefits than taking no action and incurring evergreater care costs as patients become increasingly disabled. These calls are critical to the future strategy of reducing the general burden of MS across Europe and should be acted upon with urgency. ■
